Alzheimer's Disease Stocks List

Alzheimer's Disease Stocks Recent News

Date Stock Title
Jul 5 ANVS Annovis Bio: A Close Look At Their Parkinson's Trial Data
Jul 3 ANVS Annovis stock swells after Phase III Parkinson’s subgroup success
Jul 3 BIIB Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More
Jul 3 ANVS Annovis Bio shares dip on phase III Parkinson's trial data
Jul 3 BIIB Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
Jul 3 ANVS Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
Jul 3 ANVS Tesla, Paramount Global, Annovis Bio, Eli Lilly, Amazon: Why These 5 Stocks Are On Investors' Radars Today
Jul 2 BIIB Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug
Jul 2 BIIB US Equities Markets End Higher Tuesday Following Fed Chair Powell's Comments
Jul 2 ANVS Annovis doubles as lead drug improves Parkinson’s
Jul 2 BIIB Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
Jul 2 BIIB Biogen Completes Acquisition of Human Immunology Biosciences
Jul 2 ANVS Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
Jul 2 CGTX Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
Jul 1 NXL Nexalin Technology Announces Closing of $5.2 Million Public Offering
Jul 1 AVXL Institutions own 38% of Anavex Life Sciences Corp. (NASDAQ:AVXL) shares but individual investors control 59% of the company
Jul 1 NRSN NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug
Jul 1 BIIB 10 clinical trials to watch in the second half of 2024
Jun 30 ANVS Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags